...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Wheat, Barley and Maize Target Enrichment Designs for Exome Sequencing Available from Roche NimbleGen

| Print |
Wednesday, 20 November 2013 17:45 (UTC + 1)

Roche Logo

Madison, WI, USA, November 20, 2013 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the release of SeqCap EZ Exome Designs for target enrichment of the wheat, barley and maize genomes. These agriculture exome designs were developed with key opinion leaders in crop genome research. The goal is to provide researchers a cost-effective and easy-to-use alternative sequencing method beyond whole genome sequencing.

The Wheat Barley Exome Consortium (WBEC) worked closely with Roche NimbleGen to develop both the Wheat and Barley Exome Designs for public use. The WBEC is a collaboration of researchers from the University of Liverpool, Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), James Hutton Institute, Kansas State University, University of Minnesota, University of Saskatchewan, and BIOGEMMA.  

The Maize Exome design resulted from the collaboration between Roche NimbleGen and researchers at Iowa State University and the University of Minnesota.  It is based on a comprehensive collection of the exon content from a range of North American lines of maize and maize relatives from the Zea genus.

“Using NimbleGen's target enrichment design in a maize GWAS study allowed us to focus our sequencing resources on the exome, which proved to be a more rapid and cost-effective method to identify trait associated loci over traditional detection methods,” said Dr. Patrick Schnable, Distinguished Professor and Director, Center for Plant Genomics at Iowa State University.

The advancement of plant genomics research is critical to agriculture, energy, forestry, environment and many other fields globally, where plant genomes bring a unique set of challenges to researchers. Whole genome sequencing, a commonly used approach, has been less than efficient for many applications as a cost-prohibitive and time-consuming process. With the availability of these crop exome designs, Roche NimbleGen is providing the agricultural research community an efficient tool for in-depth analysis of complex traits in genomes that are relevant to potential breeding programs.

“We are very pleased to have had this opportunity to work with leading plant genomics scientists to advance the study of the significant variations in crop genomes. The inherent advantages of the Roche NimbleGen enrichment technology enable us to continue to lead in custom designs and unconventional genomes," said Dan Zabrowski, Head of Roche Sequencing Unit. “This work is another step of our committed effort in expanding our product offerings for efficient and effective tools to advance genomic research in key areas including agricultural biology.”

For more information about Roche NimbleGen, please visit www.nimblegen.com.


About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

For life science research only. Not for use in diagnostic procedures.

NIMBLEGEN and SEQCAP are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.


For further information please contact:

Roche Sequencing
Beth Button
Phone: +1 317 847 8172
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it